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Introduction
Extraintestinal manifestations (EIMs) affecting 
joints, skin, eyes and the biliary duct represent a 
common feature in patients with inflammatory 
bowel disease (IBD). Depending on the organ 
affected and their severity, EIMs can be even 
more devastating for the patient than the actual 
intestinal disease. According to the literature 
between up to 40% of patients with IBD suffer 
from at least one EIM during the disease course.1,2 
The activity of some EIMs runs in parallel to the 
activity of intestinal inflammation, such as epis-
cleritis, peripheral arthritis, erythema nodosum 
and aphthous ulcers; however, the activity of oth-
ers such as uveitis, primary sclerosing cholangitis 
(PSC), pyoderma gangrenosum and spondyloar-
thropathy, is independent of intestinal disease 
activity.1,3–5 About 25% of patients with IBD suf-
fer from more than one EIM.6,7
Importantly, EIMs may sometimes even occur 
before the onset of intestinal disease and diagnosis 
Uveitis manifestations in patients of  
the Swiss Inflammatory Bowel Disease 
Cohort Study
Luc Biedermann, Laura Renz, Nicolas Fournier, Jean-Benoît Rossel, Matthias Butter,  
Sena Bluemel, Stephan R. Vavricka, Gerhard Rogler and Michael Scharl on behalf  
of the Swiss IBD Cohort Study Group
Abstract
Background: The knowledge about risk factors for the onset of uveitis manifestations in 
patients with inflammatory bowel disease (IBD) is still limited. Here, we aimed to provide an 
overview of the clinical factors associated with the onset of uveitis in the Swiss IBD Cohort 
Study (SIBDCS).
Methods: We included epidemiological and clinical data from 1840 patients with Crohn’s 
disease (CD) and 1426 patients with ulcerative colitis (UC) followed up in the SIBDCS between 
2006 and 2018. Associations between disease characteristics and uveitis were assessed in 
univariate and multivariate analyses.
Results: Overall, we identified 285 patients with uveitis. Uveitis was more frequent in patients 
with CD (11.1%; 205 of 1635) than UC (5.6%; 80 of 1346; odds ratio 2.11, p < 0.001). The 
occurrence of uveitis manifestations in patients with UC and CD was significantly associated 
with the onset of other extraintestinal manifestations, also in multivariate analyses. The 
onset of uveitis was associated with the hallmark features of severe disease in both CD and 
UC, including a higher clinical disease activity index and the use of immunomodulators or 
calcineurin inhibitors. In CD, uveitis was more frequent in females and showed a positive 
correlation with a positive family history of IBD.
Conclusions: Our data demonstrate that uveitis in IBD occurs more often in CD as well as in 
women and is associated with a more severe disease course. This might guide physicians’ 
awareness in at-risk patients to the presence of uveitis extraintestinal manifestations and 
help to improve patient care.
Keywords: epidemiology, inflammatory bowel disease, uveitis manifestations
Received: 12 March 2019; revised manuscript accepted: 14 June 2019.
Correspondence to:  
Michael Scharl  
Department of 
Gastroenterology and 
Hepatology, University 
Hospital Zürich, University 
of Zürich, Rämistrasse 
100, 8091 Zürich, 
Switzerland 
michael.scharl@usz.ch
Luc Biedermann  
Laura Renz  
Matthias Butter  
Sena Bluemel  
Stephan R. Vavricka  
Gerhard Rogler  
Department of 
Gastroenterology and 
Hepatology, University 
Hospital Zürich, University 
of Zürich, Zürich, 
Switzerland
Nicolas Fournier  
Jean-Benoît Rossel  
Institute of Social and 
Preventive Medicine 
(IUMSP), Lausanne 
University Hospital, 
Lausanne, Switzerland
865142 TAG0010.1177/1756284819865142Therapeutic Advances in GastroenterologyL Biedermann, L Renz
research-article20192019
Original Research
Therapeutic Advances in Gastroenterology 12
2 journals.sagepub.com/home/tag
of IBD.8 The pathogenesis of IBD-related EIMs 
to date is only poorly understood; however, a cur-
rent hypothesis suggests that shared epitopes 
between the inflamed intestinal mucosa and 
extraintestinal tissue significantly contribute to the 
occurrence of EIMs.9 Further, genetic factors 
might critically contribute to the onset of EIMs 
because EIMs are associated with genetic risk var-
iants. Particularly, the onset of ocular EIMs is 
associated with variations in the gene loci encod-
ing HLA-B27 and HLA-B58.10 Further evidence 
for a genetic background comes from case-control 
studies and epidemiologic investigations.7,11,12
After manifestations in joints and skin, the eye is 
the third major organ affected by immune-medi-
ated EIMs.1 About 4–10% of patients with IBD 
suffer from ocular EIMs, with the majority hav-
ing concomitant Crohn’s disease (CD).13,14 
Episcleritis is the most frequent ocular manifes-
tation of IBD, affecting 2–5% of patients with 
IBD. It is characterized by an increased activity 
in parallel with increased intestinal inflamma-
tion.15 In contrast, uveitis is independent from 
intestinal disease and is present in up to 3% of 
patients with IBD. It frequently precedes IBD 
diagnosis and is associated mainly with periph-
eral arthritis and is more common in women than 
men.16 A much rarer condition is scleritis, which 
is not related to intestinal disease activity and 
may either precede IBD diagnosis or occur there-
after.15 Other rare ocular manifestations in 
patients with IBD are keratinopathy and retin-
opathy/chorioretinopathy.17
From a clinical point of view, it would be essential 
to know which patient characteristics predict the 
onset of ocular manifestations, such as uveitis, in 
patients with IBD to stratify patients with IBD 
according to their risk of developing uveitis mani-
festations, increase vigilance for an early detec-
tion and to initiate appropriate treatment. The 
Swiss Inflammatory Bowel Disease Cohort Study 
(SIBDCS) featuring a large patient collective 
with long-term prospective follow up provides an 
ideal basis for the analysis of risk factors for the 
development of uveitis.
Patients and methods
Patient data
Demographic and clinical data were obtained 
from the database of the nationwide SIBDCS. 
The SIBDCS represents a Swiss-wide multi-
center prospective observational population-
based study and includes patients with IBD from 
all over Switzerland. The SIBDCS was initiated 
in the Canton of Vaud and subsequently extended 
to all of Switzerland in 2006 in a joint, multidisci-
plinary effort by gastroenterologists, pathologists, 
psychologists and bioinformatics specialists. The 
SIBDCS has been continuously funded by the 
Swiss National Science Foundation since 2006. 
To be eligible for participation in the SIBDCS, 
patients need to be diagnosed with IBD at least 
4 months before actual inclusion in the cohort. 
Repetitively applying a standardized question-
naire, patient data are collected once a year and 
entered into a central database. Exact inclusion 
and exclusion criteria and further details on the 
SIBDCS are described elsewhere.18 In this study 
on uveitis in IBD, a total number of 3266 patients 
in the SIBDCS followed from 2006 to March 
2018 were included in our analysis. Of those, 
1840 suffered from CD and 1426 from UC or 
IBD unclassified (IBDU; UC and IBDU were 
considered as one study group).
Study design
All patients from the SIBDCS (adult and pediat-
ric) suffering from either CD, UC or IBDU were 
included into our study. Regarding ocular EIMs, 
only uveitis and iritis were specifically inquired 
with a distinctive tick box to cross in the physi-
cians’ SIBDC enrollment and annual follow-up 
questionnaires. The tick box was named: uveitis/
iritis. There were no other questions regarding eye 
manifestations in the questionnaire. Therefore, in 
the retrospective setting, we cannot distinguish 
between uveitis and iritis. In addition, the SIBDCS 
questionnaire did not ask for other ocular EIMs. 
The physician’s questionnaire was filled out by the 
treating gastroenterologist. Patients were divided 
into two groups: one group with uveitis or iritis at 
the time of inclusion into the cohort or during fol-
low up, and another group without uveitis or iritis 
manifestations at any time of their disease course. 
The uveitis manifestations were diagnosed by the 
physicians involved in the care of the patient; how-
ever, from our database, the exact number of 
patients that were finally diagnosed by an ophthal-
mologist was not available.
Patients with UC and IBDU were grouped 
together. Univariate and multivariate logistic 
regression analysis was performed. The following 
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possible explanatory variables were considered: 
(1) Epidemiological characteristics: diagnosis of 
CD, UC or IBDU, sex, age at diagnosis, age at 
latest follow up, disease duration, body mass index 
(BMI) at latest follow up, smoking status and 
family history of IBD. (2) Disease characteristics 
and complications: activity index, initial and cur-
rent disease location, EIMs (i.e. other than uveitis 
including pyoderma gangrenosum, erythema 
nodosum, aphthous/oral ulcers, ankylosing spon-
dylitis and PSC), existence of CD-related compli-
cations such as stenosis, fistula, fissure, abscess, 
intestinal surgery, anemia and vitamin B12 levels. 
(3) Selected medications: 5-aminosalicylic acid 
(5-ASA), antibiotics, steroids, immunomodula-
tors (azathioprine, 6-mercaptopurin), anti-tumor 
necrosis factor (TNF) antibodies and calcineurin 
inhibitors. (4) Longitudinal data on uveitis in 
patients with CD and UC/IBDU.
The Modified Truelove and Witts activity index 
(MTWAI) and Crohn’s disease activity index 
(CDAI) were used as measures of disease activity. 
Disease activity indices were normalized to a 
value between 0 and 100 and expressed as an 
activity index. IBD medication was specified by 
the treating physician in the standardized SIBDC 
questionnaires at patient inclusion and annual 
follow-up visits.
Statistical analysis
All statistical analyses were carried out using Stata 
Software (v.14.2, StataCorp, College Station, TX, 
USA) and R software (v.3.3.1, The R Foundation 
for Statistical Computing, Vienna, Austria). 
QQ-plots were used to assess distribution of con-
tinuous data. Gaussian-distributed data were 
reported as the mean, standard deviation and 
range, while non-Gaussian data were presented as 
the median, interquartile range and range. 
Differences in means between the two independ-
ent groups were assessed using the Student’s t test. 
Differences of non-Gaussian data were assessed 
using the Mann–Whitney–Wilcoxon rank sum 
test. Categorical data were presented as raw fre-
quencies and relative percentages. Differences in 
distributions for categorical data between two or 
more groups were assessed using the Chi-square 
test, or Fisher’s exact test in the case of insufficient 
sample size, respectively. Time-to-event data were 
analysed using the Kaplan–Meier estimator, using 
specific techniques to deal with interval-censored 
data. Results were presented as cumulative 
proportion curves. Multivariate logistic regression 
was used to assess the association of multiple fac-
tors with the occurrence of uveitis. At first, all fac-
tors with univariate p value <0.200 were included 
into the multivariate model. Nonsignificant factors 
(p > 0.05) were then excluded from the model one 
by one, until all remaining factors were significant. 
In a last step, all factors that were left aside were 
once more inserted one by one into the model and 
kept, if proven significant, while checking for 
model consistency at each step of the procedure.
Ethical considerations
The SIBDCS was approved by the respective eth-
ical committees in Switzerland (Ethics Committee 
of the Canton Zürich: EK-1316). All patients 
signed an informed consent for data collection 
and analysis for research purposes. The current 
substudy has been evaluated and approved by the 
scientific board of SIBDCS.
Results
Epidemiology of uveitis in patients in the 
SIBDCS
Data from 3266 patients with IBD were analysed 
(1840 CD; 1426 UC/IBDU). Out of those 1840 
patients with CD, 877 patients were male and 
963 were female. Overall, 11.1% of patients with 
CD (205) suffered from uveitis either before 
inclusion or during participation in the SIBDCS. 
From the total number of 1426 patients with UC/
IBDU, 766 patients were male and 660 were 
female. Overall, 5.6% of patients (80) suffered 
from uveitis at any time during their disease 
course. The risk of suffering from uveitis was sig-
nificantly higher in patients with CD versus UC 
[odds ratio (OR) 2.11, 1.61–2.76; p < 0.0001].
Disease characteristics and uveitis 
manifestations in patients with CD
A total of 124 (60.5%) patients with CD with uvei-
tis were female and 81 (39.5%; p = 0.013) were 
male. Patients with CD without uveitis did not 
show any significant sex difference (51.3% female 
versus 48.7% male). Though the age at CD diagno-
sis did not significantly differ between patients with 
or without uveitis, the disease duration was clearly 
different with a median disease duration of 16 ver-
sus 12 years in patients with CD with versus without 
at the time of onset of uveitis EIMs (p < 0.001). 
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More patients without uveitis were initially diag-
nosed with disease located in the terminal ileum, 
whereas about one fifth of patients with uveitis 
manifestations presented with unknown/unclear 
disease localization at diagnosis. In contrast, no dif-
ferences were observed regarding disease localiza-
tion at the latest follow-up visit. Disease severity 
was significantly higher in patients with uveitis at 
enrollment as well as at the latest follow-up visit. 
Interestingly, patients with CD with uveitis had a 
higher rate of positive family history for IBD (18.0% 
versus 12.8%; p < 0.001; Table 1).
Complications and medical treatment in 
patients with CD and uveitis
Details of complications and medical treatment 
in patients with CD and uveitis are in Table 2. Of 
note, patients with CD with uveitis manifesta-
tions suffered more often from abscesses than 
patients without uveitis manifestations (30.2% 
versus 23.9%, p = 0.047); however, we detected 
no difference in the occurrence of perianal fistu-
las, any fistulas, other fistulas or stenosis between 
both groups. Also, there was no difference with 
respect to the number of CD-related surgeries. 
Nevertheless, patients with uveitis suffered more 
often from anemia and vitamin B12 deficiency and 
consequently more often received vitamin B12 
substitution therapy when compared with patients 
without uveitis manifestations. We detected sev-
eral important differences in the treatment history 
of the patients. Patients affected by uveitis received 
5-ASA, corticosteroids, immunomodulators and 
anti-TNF antibodies significantly more often. In 
addition, patients with uveitis also suffered consid-
erably more often from other EIMs: the risk of suf-
fering from a concomitant EIM throughout all 
individual EIMs in patients with uveitis was 
increased approximately threefold.
A higher CDAI at the latest follow-up visit, 
immunomodulatory treatment and the presence 
of other EIMs (the latter with an OR of 4.692; 
2.745–8.019, p < 0.001) were shown to be inde-
pendent risk factors for the onset of uveitis in 
patients with CD in the multivariate logistic 
regression analysis (Table 3).
Disease characteristics and uveitis in patients 
with UC/IBDU
Table 4 shows the disease characteristics and uve-
itis in patients with UC/IBDU. A total of 45 
(56.3%) male and 35 (43.7%) female patients 
with UC had uveitis manifestations. Patients with 
UC and uveitis had a significantly longer disease 
duration (median 14 versus 11 years, p = 0.001), 
and higher disease activity indices (MTWAI) at 
enrollment as well as at the latest follow up com-
pared with patients without uveitis 
manifestations.
Complications and medical treatment in 
patients with UC/IBDU and uveitis
Similar to CD, patients with UC and uveitis also 
suffered significantly more often from at least one 
other EIM with again an approximately threefold 
increased risk (2–7.5-fold depending on the 
respective EIM; Table 5). Of note, PSC was the 
only exception. More than 90% of patients with 
uveitis received corticosteroids (compared with 
78.5% without uveitis, p = 0.006) and also had 
antibiotics and calcineurin inhibitors more fre-
quently during the disease course. No difference 
between both groups was detected for the use of 
anti-TNF antibodies, immunomodulators or 
5-ASA. While patients with UC and uveitis 
received vitamin B12 substitution more often, 
there was no difference detected for IBD-related 
surgery, anemia or vitamin B12 deficiency.
The age at diagnosis, vitamin B12 supplementa-
tion, need for calcineurin inhibitors (OR: 2.285 
[1.128–4.628], p = 0.022) as well as the presence 
of other EIMs (OR: 2.858 [1.538–5.309], 
p = 0.001) were independent risk factors for the 
onset of uveitis in patients with UC in the multi-
variate logistic regression analysis (Table 6).
Longitudinal data on the onset of uveitis in 
patients with CD and UC/IBDU
In a small subset of 23 patients of the SIBDCS, 
data were available to investigate the sequence of 
uveitis versus non-uveitis longitudinally in the dis-
ease history. In the majority of patients, uveitis 
was reported as the first EIM (72.2% and 100% 
in patients with CD and UC/IBDU, respectively). 
Interestingly, while uveitis was reported before 
the initial diagnosis in the majority of patients 
with CD with this EIM (61.1%), uveitis was in 
contrast, reported after the onset of colitis in most 
patients with UC/IBDU (80% of patients with 
uveitis; Table 7). Interestingly, 11 patients with 
CD and 1 patient with UC/IBDU reported an eye 
EIM occurrence (uveitis/iritis) even before IBD 
L Biedermann, L Renz et al.
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Table 1. Disease characteristics and uveitis in patients with UC/IBDU.
No uveitis Uveitis All patients with CD p value
Number of patients 1635 (88.9) 205 (11.1) 1840 (100.0) -
Sex  
 Male 796 (48.7) 81 (39.5) 877 (47.7)  
 Female 839 (51.3) 124 (60.5) 963 (52.3) 0.013
Age at diagnosis, y
(median, IQR, range)
26, 20–36
1–81
28, 21–39
9–78
26, 20–37
1–81 0.093
Age at latest follow up, y
(median, IQR, range)
43, 32–56
16–94
50, 36–61
19–88
44, 33–56
16–94 <0.001
Disease duration, y
(median, IQR, range)
12, 7–21
0–57
16, 10–25
1–47
13, 7–21
0–57 <0.001
BMI at latest follow up, kg/m2
(median, IQR, range)
23, 20–26
14–47
23, 19–25
15–31
23, 20–26
14–47 0.430
Initial disease location  
 L1 403 (24.7) 38 (18.5) 441 (24.0)  
 L2 322 (19.7) 43 (21.0) 365 (19.8)  
 L3 733 (44.8) 85 (41.5) 818 (44.5)  
 L4 only 12 (0.7) 2 (1.0) 14 (0.8)  
 Unclear/unknown 165 (10.1) 37 (18.0) 202 (11.0) 0.008
Last disease location  
 L1 468 (28.6) 50 (24.4) 518 (28.2)  
 L2 485 (29.7) 71 (34.6) 556 (30.2)  
 L3 442 (27.0) 54 (26.3) 496 (27.0)  
 L4 only 37 (2.3) 9 (4.4) 46 (2.5)  
 Unclear/unknown 203 (12.4) 21 (10.2) 224 (12.2) 0.154
CDAI at enrollment
(median, IQR, range)
32, 11–70
0–435
63, 28–113
0–450
34, 12–76
0–450 <0.001
CDAI at latest follow up
(median, IQR, range)
20, 6–47
0–339
40, 11–72
0–345
23, 6–50
0–345 0.013
Smoking status at diagnosis  
 Nonsmoker 803 (49.1) 102 (49.8) 905 (49.2)  
 Smoker 756 (46.2) 98 (47.8) 854 (46.4)  
 Unknown 76 (4.7) 5 (2.4) 81 (4.4) 0.373
Smoking status at latest follow up  
 Nonsmoker 1100 (67.3) 144 (70.2) 1244 (67.6)  
(Continued)
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Table 2. Complications and medical treatment in patients with CD with uveitis.
No uveitis Uveitis All patients with 
CD
p value
Number of patients 1635 (88.9) 205 (11.1) 1840 (100.0) -
CD-related complications  
 Perianal fistula 415 (25.4) 62 (30.2) 477 (25.9) 0.134
 Other fistula 253 (15.5) 41 (20.0) 294 (16.0) 0.095
 Any fistula 562 (34.4) 77 (37.6) 639 (34.7) 0.366
 Abscess 391 (23.9) 62 (30.2) 453 (24.6) 0.047
 Stenosis 705 (43.1) 88 (42.9) 793 (43.1) 0.958
CD-related surgery  
 Intestinal resection 672 (41.1) 88 (42.9) 760 (41.3) 0.617
 Fistula/abscess surgery 400 (24.5) 60 (29.3) 460 (25.0) 0.134
 Any surgery 834 (51.0) 108 (52.7) 942 (51.2) 0.651
Anemia  
 During SIBDCS follow up 472 (29.4) 74 (36.6) 546 (30.2) 0.035
 At latest follow up 157 (11.8) 15 (9.7) 172 (11.6) 0.425
Vit. B12 level at latest follow up, pmol/l (median, 
IQR, range)
238, 177–324
28–2435
282, 189–408
102–1476
243, 178–328
28–2435 0.013
Ever received vit. B12 Suppl 659 (49.9) 109 (59.2) 768 (51.1) 0.018
Treatment history  
 5-ASA 925 (56.6) 135 (65.9) 1060 (57.6) 0.011
 Antibiotics 286 (17.5) 43 (21.0) 329 (17.9) 0.220
 Steroids 1399 (85.6) 186 (90.7) 1585 (86.1) 0.044
No uveitis Uveitis All patients with CD p value
 Smoker 523 (32.0) 60 (29.3) 583 (31.7)  
 Unknown 12 (0.7) 1 (0.5) 13 (0.7) 0.765
Family history of IBD  
 None 1239 (75.8) 160 (78.1) 1399 (76.0)  
 Yes 209 (12.8) 37 (18.0) 246 (13.4)  
 Unknown 187 (11.4) 8 (3.9) 195 (10.6) <0.001
BMI, body mass index; CD, Crohn’s disease; IBD, inflammatory bowel disease; IQR, interquartile range.
Table 1. (Continued)
(Continued)
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diagnosis (Table 7). The cumulative proportion 
of uveitis in CD as well as in patients with UC/
IBDU was constantly progressing, and particu-
larly in patients with CD it increased about 6% 
every 10 years of disease duration (Figure 1). Of 
note, in our database, for 201 of the 285 patients 
with uveitis (70.5%), this EIM is mentioned in 
only one questionnaire, but not in the follow-up 
questionnaire. This suggests that the uveitis had 
gone between completing the two questionnaires 
(that were routinely answered every 12 months) 
and did not reoccur.
Table 3. Multivariate logistic regression results for patients with CD.
Outcome: uveitis OR (%CI) p value
CDAI at latest follow up
(per CDAI point) 1.006 (1.003–1.010) <0.001
Immunomodulator treatment  
 Never (ref) 1 (ref) -
 Yes 1.998 (1.011–3.949) 0.047
Other EIM  
 No (ref) 1 (ref) -
 Yes 4.692 (2.745–8.019) <0.001
CD, Crohn’s disease; CDAI, Crohn’s disease activity index; CI, confidence interval; EIM, extraintestinal manifestation; IBD, 
inflammatory bowel disease; IQR, interquartile range; OR, odds ratio.
No uveitis Uveitis All patients with 
CD
p value
 Immunomodulators 1317 (80.6) 181 (88.3) 1498 (81.4) 0.007
 Anti-TNF 1006 (61.5) 147 (71.7) 1153 (62.7) 0.005
 Calcineurin inhibitors 30 (1.8) 6 (2.9) 36 (2.0) 0.287
Extraintestinal manifestations  
 Arthritis 722 (44.2) 164 (80.0) 886 (48.2) <0.001
 Pyoderma gangrenosum 21 (1.3) 8 (3.9) 29 (1.6) 0.005
 Erythema nodosum 101 (6.2) 39 (19.0) 140 (7.6) <0.001
 Aphthous/oral ulcers 170 (10.4) 68 (33.2) 238 (12.9) <0.001
 Ankylosing spondylitis 92 (5.6) 34 (16.6) 126 (6.8) <0.001
 PSC 9 (0.6) 3 (1.5) 12 (0.7) 0.141
 Any of the above 822 (50.3) 176 (85.9) 998 (54.2) <0.001
5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; IBD, inflammatory bowel disease; IQR, interquartile range; PSC, primary sclerosing cholangitis; 
SIBDCS, Swiss IBD Cohort Study; TNF, tumor necrosis factor; vit., vitamin.
Table 2. (Continued)
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Table 4. Disease characteristics and uveitis in patients with UC/IBDU.
No uveitis Uveitis All patients with UC/IBDU p value
Number of patients 1346 (94.4) 80 (5.6) 1426 (100.0) -
Sex  
 Male 721 (53.6) 45 (56.3) 766 (53.7)  
 Female 625 (46.4) 35 (43.7) 660 (46.3) 0.640
Age at diagnosis, y
(median, IQR, range)
31, 23–40
3–83
31, 25–41
12–72
31, 23–41
3–83 0.639
Age at latest follow up, y
(median, IQR, range)
45, 36–57
17–89
49, 41–59
22–77
46, 36–57
17–89 0.028
Disease duration, y
(median, IQR, range)
11, 6–18
0–59
14, 10–24
2–41
11, 6–18
0–59 0.001
BMI at latest follow up, kg/m2
(median, IQR, range)
24, 21–27
18–37
25, 24–27
20–29
24, 21–27
18–37 0.675
Initial disease location  
 Pancolitis 503 (37.4) 32 (40.0) 535 (37.5)  
 Left-sided colitis 438 (32.5) 21 (26.3) 459 (32.2)  
 Proctitis 268 (19.9) 12 (15.0) 280 (19.6)  
 Unclear/unknown 137 (10.2) 15 (18.7) 152 (10.7) 0.066
Last disease location  
 Pancolitis 470 (34.9) 24 (30.0) 494 (34.6)  
 Left-sided colitis 484 (36.0) 31 (38.8) 515 (36.1)  
 Proctitis 234 (17.4) 17 (21.2) 251 (17.6)  
 Unclear/unknown 158 (11.7) 8 (10.0) 166 (11.6) 0.676
MTWAI at enrollment
(median, IQR, range)
2, 1–5
0–19
4, 2–8
0–16
2, 1–5
0–19
<0.001
MTWAI at latest follow up
(median, IQR, range)
2, 0–4
0–18
3, 1–5
0–11
2, 0–4
0–18
0.006
Smoking status at diagnosis  
 Nonsmoker 1011 (75.1) 61 (76.3) 1072 (75.2)  
 Smoker 285 (21.2) 15 (18.8) 300 (21.0)  
 Unknown 50 (3.7) 4 (5.0) 54 (3.8) 0.701
Smoking status at latest follow up  
 Nonsmoker 1142 (84.8) 66 (82.5) 1208 (84.7) 0.447
 Smoker 184 (13.7) 14 (17.5) 198 (13.9)  
 Unknown 20 (1.5) 0 (0.0) 20 (1.4)  
(Continued)
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Table 5. Complications and medical treatment in patients with CD and uveitis.
No uveitis Uveitis All patients with UC/IBDU p value
Number of patients 1346 (94.4) 80 (5.6) 1426 (100.0) -
IBD-related surgery 143 (10.6) 13 (16.3) 156 (10.9) 0.117
Anemia  
 During SIBDCS follow up 385 (30.8) 27 (34.6) 412 (31.0) 0.477
 At latest follow up 131 (14.1) 7 (12.5) 138 (14.0) 0.740
Vit. B12 level at latest follow up, pmol/l 
(median, IQR, range)
295, 216–376
24–1696
250, 195–337
110–498
290, 215–374
24–1696 0.155
Ever received vit. B12 supplement 221 (21.7) 28 (38.9) 249 (22.8) 0.001
Treatment history  
 5-ASA 1275 (94.7) 79 (98.8) 1354 (95.0) 0.110
 Antibiotics 131 (9.7) 17 (21.3) 148 (10.4) 0.001
 Steroids 1057 (78.5) 73 (91.3) 1130 (79.2) 0.006
 Immunomodulators 815 (60.5) 55 (68.8) 870 (61.0) 0.144
 Anti-TNF 455 (33.8) 32 (40.0) 487 (34.2) 0.256
 Calcineurin inhibitors 121 (9.0) 15 (18.8) 136 (9.5) 0.004
Extraintestinal manifestations  
 Arthritis 434 (32.2) 50 (62.5) 484 (33.9) <0.001
 Pyoderma gangrenosum 19 (1.4) 6 (7.5) 25 (1.8) <0.001
 Erythema nodosum 37 (2.7) 14 (17.5) 51 (3.6) <0.001
 Aphthous/oral ulcers 67 (5.0) 10 (12.5) 77 (5.4) 0.004
 Ankylosing spondylitis 29 (2.2) 13 (16.3) 42 (2.9) <0.001
 PSC 60 (4.5) 2 (2.5) 62 (4.3) 0.404
 Any of the above 518 (38.5) 55 (68.8) 573 (40.2) <0.001
5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; IBD, inflammatory bowel disease; IBDU, IBD unclassified; IQR, interquartile range; PSC, primary 
sclerosing cholangitis; SIBDCS, Swiss IBD Cohort Study; TNF, tumor necrosis factor; UC, ulcerative colitis; vit., vitamin.
No uveitis Uveitis All patients with UC/IBDU p value
Family history of IBD  
 None 1061 (78.8) 65 (81.3) 1126 (79.0) 0.178
 Yes 140 (10.4) 11 (13.7) 151 (10.6)  
 Unknown 145 (10.8) 4 (5.0) 149 (10.4)  
IBD, inflammatory bowel disease; IBDU, IBD unclassified; IQR, interquartile range; MTWAI, Modified Truelove and Witts activity index; UC, ulcerative 
colitis.
Table 4. (Continued)
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Discussion
We report on the clinical associations of IBD with 
uveitis manifestations in the SIBDCS, a large and 
well-defined cohort of about 3300 patients. 
Current knowledge about the clinical course as 
well as the associations of uveitis is limited and 
findings in the literature are controversial. As a 
key finding, we detected that the presence of 
other EIMs is the strongest independent risk fac-
tor for the onset of uveitis in both patients with 
CD and UC. In addition, the use of immunomod-
ulators in patients with CD and calcineurin 
inhibitors in patients with UC are independently 
associated with the presence of uveitis.
Ocular manifestations represent the third most 
common EIM in patients with IBD and the fre-
quency of any ocular EIM ranges between 0.3% 
up to 13.0% in patients with IBD.19,20 The fre-
quency of ocular EIMs of 5.6% in patients with 
UC and 11.1% in patients with CD in our study 
is in line with these data, so is the more frequent 
occurrence in patients with CD as opposed to 
patients with UC.10,21,22 Comparable findings 
Table 6. Multivariate logistic regression results for patients with UC.
Outcome: uveitis OR (%CI) p value
Age at diagnosis, per year 1.028 (1.008–1.048) 0.006
Ever treated with B12 vit.  
 Never 1 (ref) -
 Yes 2.020 (1.121–3.643) 0.019
Calcineurin inhibitor treatment  
 Never 1 (ref) -
 Yes 2.285 (1.128–4.628) 0.022
Other EIM  
 No (ref) 1 (ref) -
 Yes 2.858 (1.538–5.309) 0.001
CI, confidence interval; EIM, extraintestinal manifestation; OR, odds ratio; UC, ulcerative colitis; vit., vitamin.
Table 7. Time of occurrence of uveitis in patients with IBD.
Patients with CD Patients with 
UC/IBDU
All patients with 
IBD
p value
Eye EIM occurrence compared 
with other EIMs
 
 As first EIM reported 13 (72.2) 5 (100.0) 18 (78.3)  
 As subsequent EIM 5 (27.8) 0 (0.0) 5 (21.7) 0.545
Eye EIM occurrence compared 
with diagnosis
 
 Reported before diagnosis 11 (61.1) 1 (20.0) 12 (52.2)  
 Reported after diagnosis 7 (38.9) 4 (80.0) 11 (47.8) 0.155
EIM, extraintestinal manifestation; IBD, inflammatory bowel disease; IBDU, IBD unclassified; UC, ulcerative colitis.
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were obtained also in the pediatric IBD popula-
tion in a large systematic review and meta-analy-
sis including 7467 pediatric patients.23
In the literature, ocular manifestations are gen-
erally more frequent in female patients in both, 
CD and UC;2,10,24 however, in our large patient 
collective, we found somewhat in contrast, a 
female preponderance of ocular uveitis EIMs 
only in patients with CD but not in patients with 
UC. Overall, in our cohort we detected a sub-
stantially higher frequency of ocular EIMs com-
pared with the reported occurrence in the 
literature, particularly for instance to Bernstein 
and colleagues.2
The most striking finding in our cohort is that the 
presence of uveitis was clearly associated with the 
onset of other EIMs, mainly arthritis and ery-
thema nodosum. In addition, the presence of 
uveitis correlated with markers of a severe disease 
course, particularly the use of immunomodula-
tors or calcineurin inhibitors, suggesting that the 
occurrence of uveitis per se may be considered a 
marker of a more severe disease course. This is 
supported by our finding of a significantly higher 
CDAI in patients with CD and uveitis than their 
counterparts without uveitis. An association of 
ocular EIMs with the onset of arthritis and ery-
thema nodosum was also demonstrated in a 
recent study of approximately 3450 patients in 
the United States with IBD.25 In this study, the 
gene locus encoding RBM19 was also signifi-
cantly associated with the onset of ocular EIMs. 
This might indicate a pathophysiological link 
between the underlying mechanisms for the 
occurrence of ocular manifestations and thus, a 
potential predictive biomarker.25
Surprisingly, even though smoking is associated 
with a severe disease course in CD, we did not 
find any correlation between smoking and the 
onset of uveitis in our patient collective, confirm-
ing findings of a smaller study by Isene and col-
leagues from 2015.26 However, in contrast with 
the data from Isene and colleagues, we found a 
significant positive correlation between a family 
history of IBD and the onset of ocular manifesta-
tions in patients with CD.26
Form a clinical perspective, it is important to 
know the actual type of ocular manifestation that 
a patient with IBD is suffering from. Since there 
are sometimes severe courses of ocular inflam-
mation, an appropriate treatment requiring sys-
temic corticosteroids or immunosuppressive 
Figure 1. Cumulative proportion of uveitis in the SIBDCS.
CD, Crohn’s disease; EIM, extraintestinal manifestation; IBDU, IBD unclassified; SIBDCS, Swiss IBD Cohort Study; UC, 
ulcerative colitis.
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medications/biologicals is often necessary. 
Anterior uveitis and uveitis with an uncompli-
cated course can be treated with topical corticos-
teroids. However, severe cases of uveitis or 
scleritis might need treatment with systemic cor-
ticosteroids or, to reduce corticosteroids in the 
long-term, other immunosuppressive medica-
tion or biologics. However, such treatment 
should always include the opinion of an ophthal-
mologist before it is initiated. In contrast, epis-
cleritis is often self-limiting or responds to 
topical approaches.19
Our study has several strengths, but also limita-
tions. The very large patient collective of the 
SIBDCS with a highly standardized longitudinal 
follow up is a strength. In fact, our study is one of 
the biggest studies to date associating ocular 
manifestations with disease characteristics in 
IBD. Nevertheless, our study has also some limi-
tations. First, the questionnaires routinely only 
asked for uveitis/iritis by a check box. Other ocu-
lar EIMs could be entered in a free-text field; 
however, this might have led to an underrepre-
sentation. In fact, we could only detect 29 patients 
with eye manifestations other than uveitis (data 
not shown). Second, although the vast majority of 
patients with ocular EIMs are seeing expert oph-
thalmologists, we cannot rule out that some diag-
noses of uveitis were made by nonopthalmologists 
with consecutive risk of over- or underdiagnosis 
of uveitis and iritis, or even a different ophthal-
mologic diagnosis, respectively. Third, as uveitis 
and iritis were recorded simultaneously in the 
SIBDCS questionnaires, we were not able to dis-
tinguish between these two ophthalmologic enti-
ties. Fourth, since the questionnaire of our cohort 
did not specifically ask for the treatment of eye 
EIMs, we cannot discriminate whether a treat-
ment was initiated because of the eye EIM or, 
more likely, because of the intestinal IBD 
symptoms.
Our data provide an overview about the clinical 
associations and implications of uveitis in patients 
with IBD. We demonstrate that uveitis occurs in 
about one tenth of our patients, and therefore 
recognition of ocular manifestations is of crucial 
relevance for daily clinical practice. Additionally, 
the identification of risk factors for uveitis in 
patients with IBD, which can precede the onset of 
intestinal inflammation, may help to improve 
diagnosis of IBD and also of the ocular involve-
ment. Our data might contribute to an increased 
physician awareness for the presence of ocular 
EIMs in patients with IBD, possibly leading to 
earlier diagnosis, prompt tailored therapeutic 
measures and finally improved care of patients 
with IBD.
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